| Molecular formula | C46H65N13O12S2 |
|---|
| Molecular weight | 1056.2 g/mol |
|---|
| Registered trials | 87 |
|---|
| PubChem CID | 644076 |
|---|
What Lypressin Is
Lypressin is a peptide compound identified by PubChem CID 644076, with a molecular formula of C46H65N13O12S2. It does not have an approved FDA label, and it is classified here as an unapproved research compound. No indications, mechanism of action, or brand names can be confirmed without a label on file.
Trial Footprint
A total of 87 clinical trials are registered that reference lypressin or closely related vasopressin analogs. Some of the sampled trials involve terlipressin, a related compound, rather than lypressin itself. Listed studies include a Phase 4 trial on hepatorenal syndrome treatment with terlipressin plus albumin (status: suspended), a Phase 2 trial examining terlipressin's effect on portal vein pressure after liver resection (status: unknown), and a completed trial with no assigned phase comparing terlipressin to octreotide in hepatorenal syndrome patients. These entries illustrate the broader research landscape surrounding vasopressin-class peptides rather than confirmed data specific to lypressin.
FAQ
No, lypressin does not have an approved FDA label in the data reviewed. It is classified as an unapproved research compound.
Because no approved label exists, there is no confirmed approved use to describe. Available information is limited to its chemical identity and its presence in a broader set of registered clinical trials.
There are 87 registered clinical trials associated with lypressin and closely related vasopressin analogs. The sampled trials in this dataset largely involve terlipressin, a related peptide, studied in conditions like hepatorenal syndrome and portal vein pressure management.
Lypressin is cataloged in PubChem under CID 644076, with the molecular formula C46H65N13O12S2 and a molecular weight of approximately 1056.2. This chemical identity is confirmed independent of its regulatory or clinical trial status.
No side effect reporting data (FAERS) was available for lypressin in the reviewed dataset. This does not confirm the absence of side effects, only that no data was provided.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-09-19